Dan Weiss

Dan Weiss
APPY- Bovipure deletion was a mistake. Still on track with Novartis per Greg Pusey.

Dan Weiss
APPY-mgmt has lost some credibility in the inst space with their vague PR. Based on conversation w/co more info to come within next 8 weeks.

Dan Weiss
APPY- those are both very valid questions but unfortunately we will not know the answers until the full release is made.

Dan Weiss
APPY- company says that they are holding off on a conference call until they can present full data to investment community.

Dan Weiss
APPY- variability in site results causing a delay- hopefully not a major issue. No additional info at this point. APPY targets under review

Dan Weiss
APPY: received confirmation that clinical results release either later this week or next week.

Dan Weiss
Aspenbio (APPY): Timing update: company is expecting to issue clinical data concurrently with 510K submittal during this qtr (May or June).

Dan Weiss
APPY: Spoke with co. Offering sold out, no changes to expected timeline- plan to file 510K by end of Q2 as discussed previously.

Dan Weiss
APPY update: Company offering $10 million of common stock at $4.15/share with warrant kicker exerciseable at $4.85. Buying opportunity.